This is a working overview of peptide backbone, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
I am ready to meet all our politicians; we have to work together for the common good of Serbia, and to be friends in the name of the future of our country. I appeal for the end of the continuous political wrangling, division and arguments. I appeal for mature democratic debate in the interest of Serbia. Serbia must have clear and realistic objectives. In 2011, an online open access poll by Serbian middle-market tabloid newspaper Blic showed that 64% of Serbians support restoring the monarchy. Another poll in May 2013 had 39% of Serbians supporting the monarchy, with 32% against it. The public also had reservations with Alexander's apparent lack of knowledge of the Serbian language. On 27 July 2015, newspaper Blic published a poll "Da li Srbija treba da bude monarhija?" ("Should Serbia be a monarchy?"); 49.8% respondents expressed support in a reconstitution of monarchy, 44.6% were opposed and 5.5% were indifferent. In 2017, an NGO, the Kingdom of Serbia Association, announced that in 2016, they had collected over 123,000 signatures of support for a referendum on Alexander being named king, short of the 150,000 needed to force a constitutional amendment.
==== Oral isotretinoin ==== Oral isotretinoin (retinoic acid isomer) is recommended for treating treatment resistant acne, acne that can lead to scarring, and acne that is associated with psychosocial distress. It is approved by the FDA for treating severe acne vulgaris that is resistant to other treatment options. Isotretinoin is a known teratogen, with an estimated 20–35% risk of physical birth defects to infants that are exposed to isotretinoin in utero, including numerous congenital defects such as craniofacial defects, cardiovascular and neurological malformations or thymic disorders. Neurocognitive impairments in the absence of any physical defects has been established to be 30–60%. For these reasons, physician- and patient-education programs were initiated, recommending that for women of child-bearing age, contraception be initiated a month before starting oral (or topical) isotretinoin, and continue for a month after treatment ended. In the US, isotretinoin was released to the market in 1982 as a revolutionary treatment for severe and refractory acne vulgaris. It was shown that a dose of 0.5–1.0 mg/kg body weight/day is enough to produce a reduction in sebum excretion by 90% within a month or two, but the recommended treatment duration is 4 to 6 months. The mechanism by which orally consumed retinoic acid (RA), as all-trans-tretinoin or 13-cis-isotretinoin improves facial skin health is thought to be by switching on genes and differentiating keratinocytes (immature skin cells) into mature epidermal cells.
The Napoleonic Wars (1803–1815) were a global series of conflicts fought by a fluctuating array of European coalitions against the French First Republic (1803–1804) under the First Consul followed by the First French Empire (1804–1815) under the Emperor of the French, Napoleon. The wars originated in political forces arising from the French Revolution (1789–1799) and French Revolutionary Wars (1792–1802) and produced a period of French domination over continental Europe. The wars are categorised as seven conflicts, five named after the coalitions that fought Napoleon, plus two named for their respective theatres: the War of the Third Coalition, War of the Fourth Coalition, War of the Fifth Coalition, War of the Sixth Coalition, War of the Seventh Coalition, the Peninsular War, and the French invasion of Russia. The first stage of the wars broke out when Britain declared war on France on 18 May 1803. After minor campaigns, Britain allied with Austria, Russia, and minor powers, to form the Third Coalition in April 1805. Napoleon defeated the allied Russo-Austrian armies in the subsequent war which climaxed in French victories at Ulm and at Austerlitz, leading to the dissolution of the Holy Roman Empire and Austria being forced to make peace. Britain and Russia remained at war with France. Concerned about increasing French power, Prussia joined Britain and Russia in the Fourth Coalition, which resumed war in October 1806.
Additionally, LOX expression is an indicator of 5-year survival in patients, with a 71% chance of survival for patients with low LOX levels, compared to 43% for patients with high LOX levels. Thus, upregulation of lysyl oxidase is a predictor of poor prognosis in early-stage adenocarcinoma patients. Lysyl oxidase has been newly implicated in tumor angiogenesis, or blood vessel formation, both in vivo and in vitro. Subcutaneous tumor-derived LOX was shown to increase vascular endothelial growth factor (VEGF) expression and secretion, which then promotes angiogenesis by phosphorylation of protein kinase B, or Akt, through platelet-derived growth factor receptor β (PDGFRB). High levels of LOX were associated with high blood vessel density in patient samples. Clinically relevant LOX inhibitors may help slow cancer progression by downregulating crucial growth factors that promote solid tumor progression. Hence, inhibitors of the LOX enzyme may be useful in preventing angiogenesis, tumor progression, and metastasis as well as treating other fibrotic disease involving remodeling of the extracellular matrix, including neurodegenerative and cardiovascular diseases.
=== Therapeutic potential === Further research into myostatin and the myostatin gene may lead to therapies for muscular dystrophy. The idea is to introduce substances that block myostatin. A monoclonal antibody specific to myostatin increases muscle mass in mice and monkeys. A two-week treatment of normal mice with soluble activin type IIB receptor, a molecule that is normally attached to cells and binds to myostatin, leads to a significantly increased muscle mass (up to 60%). It is thought that binding of myostatin to the soluble activin receptor prevents it from interacting with the cell-bound receptors. In September 2020 scientists reported that suppressing activin type 2 receptors-signalling proteins myostatin and activin A via activin A/myostatin inhibitor ACVR2B – tested preliminarily in humans in the form of ACE-031 in the early 2010s – can protect against both muscle and bone loss in mice. The mice were sent to the International Space Station and could largely maintain their muscle weights – about twice those of wild type due to genetic engineering for targeted deletion of the myostatin gene – under microgravity. Treating progeric mice with soluble activin receptor type IIB before the onset of premature ageing signs appear to protects against muscle loss and delay age related signs in other organs. It remains unclear as to whether long-term treatment of muscular dystrophy with myostatin inhibitors is beneficial, as the depletion of muscle stem cells could worsen the disease later on. As of 2012, no myostatin-inhibiting drugs for humans are on the market.
Sources: en.wikipedia.org
=== Military === In 2026, Schmitt blocked a measure to fund the U.S. Coast Guard during a partial government shutdown. While the U.S. Department of Defense was funded, and other five branches of the military were paid, the Coast Guard is a part of the Department of Homeland Security due to its law enforcement authorities and worked without the guarantee they would be paid.
== Etymology == The term forensic stems from the Latin word, forēnsis (3rd declension, adjective), meaning "of a forum, place of assembly". The history of the term originates in Roman times, where many judicial processes, such as trials and preliminary hearings, were held in the forum. This origin is the source of the two modern usages of the word forensic—as a form of legal evidence; and as a category of public presentation. In modern use, the term forensics is often used in place of "forensic science". The word "science", is derived from the Latin word for 'knowledge' and is today closely tied to the scientific method, a systematic way of acquiring knowledge. Taken together, forensic science means the use of scientific methods and processes for crime solving.
== Death and legacy == On 7 February 2025, Antonov, at age 53, died in Paris from undisclosed causes. The news was first revealed on Marc Laidlaw's Instagram story a week later, and was confirmed in a statement from Eschatology Entertainment. Many of Antonov's former colleagues paid tribute to him on social media. Laidlaw and Raphaël Colantonio respectively wrote that he was a "visionary" who was "instrumental to the success of Arkane Studios". Ex-Valve writer Chet Faliszek said that he was a "breath of fresh air at Valve", and Arkane designer Harvey Smith praised his "dry, devastating wit". Valve artist Laura Dubuk recalled he was helpful as her mentor when she started at the company. Multiple outlets noted Antonov's influence on the games industry. Aftermath writer Luke Plunkett said that he was key "in defining the visual style of some of most visually-striking video games" ever, which, as John Walker wrote for Kotaku, are "some of the most loved games of all time". Engadget writer Igor Bonifacic claimed, "if there's one person who helped make Half-Life 2 so memorable, it's Antonov", and for Rock Paper Shotgun, Edwin Evans-Thirlwell said that City 17 "continues to influence more pessimistic sci-fi game developers today".
When HypSys is silenced the production of protease inhibitors induced by wounding is halved compared to wild type plants indicating that both systemin and HypSys are required for a strong defence response against herbivores in tomato. When applied through cut petioles in Petunia, HypSys did not induce the production of protease inhibitors, but instead increased expression of defensin, a gene which produces a protein that inserts into microbial membranes, forming a pore. Defensin expression is also induced by AtPEP1. Tomato plants over-expressing systemin produced more volatile organic compounds (VOCs) than normal plants and parasitoid wasps found them more attractive. Systemin also upregulates the expression of genes involved in the production of biologically active VOCs. Such a response is crucial if antinutritional defences are to be effective, since without predators, developing insects would consume more plant material while completing their development. It is likely that VOC production is upregulated through different pathways, including oxylipin pathway that synthesises jasmonic acid aldehydes and alcohols that function in wound healing. Different AtPeps may allow A. thaliana to distinguish between different pathogens. When inoculated with a fungus, oomycete and a bacterium, the increases in AtPep expression varied depending on the pathogen. A. thaliana overexpressing AtProPep1 was more resistant to the oomycete Phythium irregulare.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.